arrow Log In to View Account     |          

Wednesday, October 9th 9:00 PM EST

Presenters: Michael W. Jann, PharmD, FCP, FCCP, BCPP,
and Sheldon J. Rich, RPh, PhD

This webcast will provide live credit (L) for those states requiring it.

Affecting over 1 million people in the United States, Parkinson’s Disease (PD) is usually diagnosed in patients over 50 years of age and renders the majority of patients disabled 10 to 15 years after disease onset. The cardinal manifestations resulting from disease progression ultimately leave patients entombed within their own bodies, often necessitating complex treatment regimens, frequent hospitalization, and oftentimes institutionalization. Because substantial neuronal damage has already occurred by the time patients are accurately diagnosed, timely recognition of symptoms and referral to a neurologist are critical. Early diagnosis is particularly important since disease-modifying therapies provide greater benefit to patients with early versus advanced-stage PD. Managed care and community pharmacists play an integral role in managing patients with early-stage PD by simplifying complex drug regimens, providing valuable information for both clinicians and patients throughout therapy, managing adverse events and drug interactions, and recognizing therapy-related problems early on in treatment. This live webcast is designed to provide community and managed care pharmacists with the most up-to-date information on identification and management strategies for patients with early-stage PD to enhance patient care.

This educational activity will provide community and managed care pharmacists education about the evolving strategies in treating and managing patients with early-stage PD, as well as the management of complex dosing regimens and associated adverse events and drug interactions.

  • Activity Overview and Goals
  • Parkinson’s: The Disease
  • Implications for Managed Care and Community Pharmacists
  • Managing Drug Reactions and Interactions
  • Pharmacoeconomic of Managing Early Stage Parkinson’s Disease
  • Conclusions

This activity is designed for community and managed care pharmacists. No prerequisites required.

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • IDENTIFY signs and symptoms related to early stages of PD.
  • EVALUATE treatment options for patients with early-stage PD.
  • DISCUSS approaches for effectively balancing efficacy and tolerability of therapy in early-stage and progressing PD.
  • UTILIZE strategies for improving medication adherence in patients with PD.

Glen Farr, PharmD (Course Director)
Professor of Clinical Pharmacy and Associate Dean
University of Tennessee
College of Pharmacy
Knoxville, TN

Michele A. Faulkner, PharmD
Associate Professor of Pharmacy
Practice and Neurology
Creighton University Schools of Pharmacy and Health Professions and Medicine
Omaha, NE

Michael W. Jann, PharmD, FCP, FCCP, BCPP
Professor and Chair
Department of Pharmacotherapy
University of North Texas System College of Pharmacy
Fort Worth, TX

Sheldon J. Rich, RPh, PhD
President, SJR Associates, LLC
Palm Beach Gardens, FL
Clinical Assistant Professor
University of Michigan
Adjunct Assistant Professor
Wayne State University
Detroit, MI

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based program will provide a statement for 1.5 live contact hours of credit (0.15 CEU). Successful completion includes participating in the activity, completing a self-assessment instrument, and completing an evaluation instrument. A statement of participation will be available online immediately following successful completion of the activity. ACPE Program Number: 0064-0000-13-210-L01-P.

Your CE credits will also be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website ( or contact NABP Customer Service: or telephone 847-391-4406.

NABP e-PROFILE ID NUMBER: To receive credit for your participation in this course, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth on the last page of the evaluation form.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.